Shenzhen Cellbri Bio-Innovation Technology
Automated, flexible manufacturing systems for cell therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor investor | €0.0 | round | |
* | N/A Valuation: CNY2.0b | Series B | |
| Total Funding | 000k | ||
Shenzhen Cellbri Bio-Innovation Technology Co., Ltd., founded in March 2020, develops and provides manufacturing solutions for the cell and gene therapy (CGT) industry. The company was founded by Shang Yuanfang, who holds a doctoral degree from Tsinghua University, along with partners from the university's Department of Precision Instrument. Lured by Shenzhen's entrepreneurial culture, Shang established the company to focus on the technological innovation and localization of key upstream manufacturing technologies and equipment for the CGT sector.
Cellbri offers a portfolio of automated, closed, and modular systems designed to handle the entire cell therapy manufacturing workflow. This includes products for PBMC separation, sorting activation, gene modification, cell washing, and fill-and-finish operations. The company's product lines, such as the 'Gentle Series' and the all-in-one 'CellFAB Series', are designed to be flexible, reducing manual handling, minimizing contamination risks, and shortening development timelines by up to 30%. These systems are not locked into proprietary reagents, giving clients like biotechnology firms, pharmaceutical companies, and CDMOs greater process control.
The company's business model is centered on selling these advanced, regulatory-compliant instruments to the life sciences industry, enabling them to accelerate drug development and reduce production costs. Cellbri has established partnerships with multiple industry companies and supports numerous clinical pipelines from early research to Phase III trials. The venture capital-backed company is currently in a revenue-generating stage, having completed a Series B1 funding round in March 2025.
Keywords: cell therapy manufacturing, gene therapy equipment, CGT upstream processing, automated cell processing, modular bioprocessing systems, PBMC separation, viral transduction, fill-and-finish systems, CAR-T manufacturing, biopharmaceutical equipment, GMP-ready automation, life sciences manufacturing, cell processing automation, closed system cell therapy, biotechnology equipment